Liraglutide

Liraglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), the incretin hormone released by intestinal L-cells after a meal. Native human GLP-1 is a poor medicine: it is degraded within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4) and cleared rapidly by the kidney. Liraglutide was engineered specifically to survive that fate while keeping the parent molecule almost intact.

The molecule is a 31-amino-acid peptide built on the human GLP-1(7-37) backbone, and it retains 97% amino acid sequence homology with that native sequence. Only two changes separate it from the human hormone. First, the lysine at position 34 is replaced by arginine. Second, a C16 palmitic acid chain is attached through a gamma-glutamyl spacer to the remaining lysine at position 26. Its molecular formula is C₁₇₂H₂₆₅N₄₃O₅₁ and its molecular weight is 3751.2 g/mol.

That near-identity to the human hormone is what distinguishes liraglutide from the first generation of GLP-1 receptor agonists. Exenatide, the first agent in the class to be approved, is derived from exendin-4, a peptide isolated from Gila monster venom, and is structurally far more distant from human GLP-1. Liraglutide, by contrast, was designed as a minimally modified human analogue, and the acylation is the single design decision that made once-daily administration possible.

The fatty acid chain does two things at once. At the injection site, the hydrophobic chains drive liraglutide molecules to self-associate into larger aggregates, which slows absorption from subcutaneous tissue. In the circulation, the same chain binds the molecule tightly to serum albumin, which shields the peptide from DPP-4 cleavage and keeps it above the threshold for glomerular filtration. The combined effect is an elimination half-life of approximately 13 hours, long enough for once-daily administration but considerably shorter than the weekly agents that followed it. Readers who want the broader pharmacology of the class will find it in our GLP-1 guide.

Liraglutide binds and activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, pancreatic alpha cells, gastric smooth muscle, cardiac tissue, kidney, and several populations of neurons in the hypothalamus and brainstem. Receptor activation raises intracellular cyclic AMP and triggers protein kinase A signalling.

In the pancreas, the dominant effect is glucose-dependent insulin secretion. Liraglutide amplifies insulin release when blood glucose is elevated and that amplification falls away as glucose normalises, which is why GLP-1 receptor agonists used as monotherapy carry a low intrinsic risk of hypoglycaemia compared with insulin or sulfonylureas. The molecule also suppresses inappropriately high glucagon secretion from alpha cells, reducing hepatic glucose output.

Outside the pancreas, liraglutide slows gastric emptying and acts on central appetite circuits. Receptor populations in the arcuate nucleus of the hypothalamus and in the area postrema and nucleus tractus solitarius of the brainstem mediate reduced hunger, increased satiety, and lower food reward signalling. These central and gastric effects, rather than any direct action on adipose tissue, account for the weight reduction observed in the obesity trials. They also account for the characteristic gastrointestinal adverse effects, which are discussed in more detail in our overview of GLP-1 side effects.

One mechanistic point is worth stating precisely, because it is frequently overstated in consumer coverage. Liraglutide activates a single receptor. The more recent agent tirzepatide is a dual agonist that also engages the GIP receptor, and several molecules now in development add glucagon receptor activity. Liraglutide belongs to the simpler, single-receptor generation of the class, and its efficacy ceiling in the published trials reflects that.

Liraglutide was developed by Novo Nordisk under the code NN2211 and reached the market first as a diabetes medicine. The European Commission granted a marketing authorisation valid across the European Union for Victoza on June 30, 2009. The US Food and Drug Administration approved Victoza for adults with type 2 diabetes on January 25, 2010.

The weight-management indication followed almost five years later. The same active substance, supplied at a higher strength under the brand name Saxenda (liraglutide 3 mg), was approved by the FDA on December 23, 2014 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. The European authorisation for Saxenda followed on March 23, 2015, and the Australian Therapeutic Goods Administration entered Saxenda on the Australian Register of Therapeutic Goods on December 24, 2015.

Both indications were later extended to younger populations. Victoza carries an indication for children aged 10 years and older with type 2 diabetes, and Saxenda was extended to adolescents aged 12 years and older with obesity on the strength of the SCALE Teens trial. That trial, published by Kelly and colleagues in the New England Journal of Medicine in 2020, randomised 125 adolescents to liraglutide and 126 to placebo alongside lifestyle therapy, and reported a significantly greater reduction in BMI standard-deviation score with liraglutide.

The sequence of approvals matters for interpreting the evidence base. Liraglutide accumulated its diabetes data first, its cardiovascular outcome data second, and its obesity data on a partly separate trial programme. The two indications are supported by different trials in different populations, and figures from one should not be transferred to the other. For the practical differences between the diabetes and obesity presentations, see our comparison of Ozempic versus Saxenda.

LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results, NCT01179048) is the single most consequential trial in the liraglutide record. Published by Marso and colleagues in the New England Journal of Medicine in 2016, it randomised 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide or placebo on top of standard care, across 410 sites in 32 countries.

Over a median follow-up of 3.8 years, the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke occurred in 608 of 4,668 patients in the liraglutide group (13.0%) and 694 of 4,672 in the placebo group (14.9%), a hazard ratio of 0.87 (95% CI, 0.78 to 0.97). Death from cardiovascular causes occurred in 219 patients (4.7%) on liraglutide versus 278 (6.0%) on placebo, a hazard ratio of 0.78 (95% CI, 0.66 to 0.93). Death from any cause occurred in 381 patients (8.2%) versus 447 (9.6%), a hazard ratio of 0.85 (95% CI, 0.74 to 0.97).

A prespecified secondary analysis of renal endpoints was published separately by Mann and colleagues in 2017. Liraglutide reduced a composite renal outcome, but the result was driven largely by a lower rate of new-onset persistent macroalbuminuria rather than by the harder components. Rates of persistent doubling of serum creatinine and of end-stage kidney disease were low in both arms. Rates of renal adverse events were similar between groups (15.1 versus 16.5 events per 1,000 patient-years), including acute kidney injury (7.1 versus 6.2 events per 1,000 patient-years).

Two constraints on LEADER deserve emphasis. The trial enrolled people with type 2 diabetes at high cardiovascular risk, not people with obesity and normal glucose metabolism, so its cardiovascular findings cannot be extrapolated to the latter group. And the absolute difference in the primary outcome was 1.9 percentage points over nearly four years, a real but modest effect that is best described in absolute rather than relative terms.

The SCALE programme supplied the evidence for the weight-management indication. Its pivotal trial, SCALE Obesity and Prediabetes (NCT01272219), was published by Pi-Sunyer and colleagues in the New England Journal of Medicine in 2015. It randomised 3,731 adults without type 2 diabetes to liraglutide 3.0 mg or placebo, both alongside diet and exercise counselling, for 56 weeks.

Mean body weight change from baseline was 8.0% with liraglutide versus 2.6% with placebo, corresponding to roughly 8.4 kg and 2.8 kg respectively. The proportion of participants losing at least 5% of baseline weight was 63.2% with liraglutide versus 27.1% with placebo, and the proportion losing more than 10% was 33.1% versus 10.6%. The trial also reported improvements in markers of glycaemic control and a reduced rate of progression to type 2 diabetes among participants with prediabetes at baseline.

Companion trials extended the programme into adjacent populations. SCALE Diabetes evaluated liraglutide 3.0 mg in adults with overweight or obesity and coexisting type 2 diabetes, where mean weight loss was smaller than in the non-diabetic population, a pattern consistent across the entire GLP-1 class. SCALE Teens, described above, supported the adolescent extension, and reported gastrointestinal adverse events in 65% of liraglutide recipients versus 37% on placebo.

Read together, the SCALE results place liraglutide firmly in the single-digit percentage range for mean weight reduction at one year under trial conditions, with substantial variation between individuals. That is clinically meaningful by the standards of 2014, when the indication was granted, and it is the benchmark against which every later agent in the class has been measured. Trial populations received structured counselling and intensive follow-up that are rarely replicated in routine practice, so real-world results commonly fall below trial averages.

There is one well-conducted head-to-head trial, and it is unambiguous. STEP 8 (NCT04074161), published by Rubino and colleagues in JAMA in January 2022, randomised adults with overweight or obesity and without diabetes to weekly subcutaneous semaglutide 2.4 mg or daily liraglutide 3.0 mg for 68 weeks. Mean weight change was minus 15.8% with semaglutide versus minus 6.4% with liraglutide, a difference of 9.4 percentage points (95% CI, minus 12.0 to minus 6.8).

The response-rate data from STEP 8 are equally stark. Participants achieving at least 10% weight loss were 70.9% with semaglutide and 25.6% with liraglutide; at least 15%, 55.6% versus 12.0%; at least 20%, 38.5% versus 6.0%. In other words, the proportion of people reaching the largest weight-loss categories differed by roughly sixfold.

No equivalent head-to-head phase 3 trial of liraglutide against tirzepatide has been published. Comparisons between those two agents therefore rest on cross-trial inference, which is methodologically weaker: the trials differ in duration, in population, in lifestyle co-intervention and in the handling of discontinuations. The tirzepatide obesity programme has reported larger mean reductions than the liraglutide programme, but the absence of a direct comparison means any numerical gap between them should be treated as an estimate rather than a measured difference.

Liraglutide's remaining distinctions are practical rather than a matter of efficacy. It has the longest post-marketing safety record in the class, with over fifteen years of continuous use since 2010. It is the only GLP-1 receptor agonist with both diabetes and obesity indications now available in generic form. And its shorter half-life means plasma concentrations fall more quickly after the last administration, which some clinicians regard as relevant in people who have previously tolerated the class poorly. These are clinical judgments for a prescriber to make, not conclusions a reader should draw independently.

Liraglutide became the first GLP-1 receptor agonist to face generic competition, and the transition unfolded across 2024 and 2025 on both sides of the Atlantic. In the United States, Teva announced the launch of an authorized generic of Victoza (liraglutide injection 1.8 mg) on June 24, 2024, following a 2019 patent litigation settlement with Novo Nordisk. A traditional abbreviated new drug application generic of the diabetes presentation was approved in late December 2024.

The weight-management presentation followed. In August 2025, the FDA approved a generic of Saxenda, reported as the first generic GLP-1 receptor agonist indicated specifically as an adjunct to diet and exercise for chronic weight management in the United States. That approval opened the first route to a lower-cost GLP-1 product for weight management in that market.

In Europe, Adalvo secured the first EU generic approval for a liraglutide pre-filled pen in June 2024 via the decentralised procedure, referencing Victoza. Biocon and its European partner obtained decentralised procedure approval in December 2024 for generic versions referencing both Victoza and Saxenda, and Biocon's liraglutide had already become the first UK-approved generic referencing Victoza in March 2024.

The paradox of the generic era is that it coincided with the withdrawal of the originator brands. The European Medicines Agency has confirmed that Novo Nordisk will stop marketing Victoza across the EU and EEA by the end of 2026, with national timelines varying but completion expected in all member states by December 2026, for commercial rather than safety or quality reasons. Novo Nordisk has separately announced discontinuation of the Saxenda brand in the United States, with final shipments to wholesalers reported for January 2027, again a portfolio decision rather than a safety action. Generic liraglutide products remain authorised. Availability by country is changing quickly, and a pharmacist or prescriber is the only reliable source on what is currently supplied locally.

The dominant adverse effects of liraglutide are gastrointestinal, and they are common rather than rare. The approved labelling lists nausea, diarrhoea, vomiting, decreased appetite, dyspepsia and constipation among the most frequent adverse reactions. In SCALE Teens, gastrointestinal adverse events affected 65% of liraglutide recipients compared with 37% on placebo, which gives a sense of the scale of the difference against background rates. These effects are generally most pronounced early in treatment and during strength escalation, and they are a frequent reason for discontinuation.

Several less common but more serious risks appear in the labelling as warnings and precautions. Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists including liraglutide, and the labelling directs that treatment be discontinued if pancreatitis is suspected; people with a history of pancreatitis are described as being at higher risk. Acute gallbladder disease, including cholelithiasis and cholecystitis, is a recognised risk, and the labelling indicates gallbladder investigation where these are suspected. Other labelled concerns include hypersensitivity reactions, increased heart rate, renal impairment in the context of volume depletion from gastrointestinal losses, and suicidal behaviour and ideation.

Liraglutide also carries a boxed warning in the United States concerning thyroid C-cell tumours. The warning states that liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures in both sexes of rats and mice, and that it is unknown whether the product causes thyroid C-cell tumours, including medullary thyroid carcinoma, in humans. The human relevance of the rodent finding has not been determined. This distinction between an established rodent signal and an unestablished human risk is the correct way to read that warning, in either direction.

Risk of hypoglycaemia with liraglutide alone is low because its insulinotropic effect is glucose-dependent, but that risk rises substantially when it is combined with insulin or a sulfonylurea. Interactions with other medicines can also arise from delayed gastric emptying affecting the absorption of co-administered oral drugs. A fuller treatment of tolerability across the class is available in our article on GLP-1 side effects. This section describes documented risks for educational purposes and is not a substitute for the full prescribing information or for an individual assessment by a qualified healthcare professional.

Liraglutide is an approved prescription medicine in all four of the major regulatory jurisdictions considered here. It is not a research-only compound, and it is not legally available without a prescription in any of them. The details differ by region, and the picture has shifted materially during 2026.

United States. Liraglutide is FDA-approved for type 2 diabetes (since January 25, 2010) and for chronic weight management (since December 23, 2014), with paediatric extensions in both indications. Generic versions are approved for both presentations. On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, stating that after evaluating the nominations it had not identified a clinical need for outsourcing facilities to compound these substances from bulk. The proposal was published in the Federal Register on May 1, 2026. If finalised, 503B outsourcing facilities would not be able to compound liraglutide from bulk drug substances, since neither the 503B bulks list nor the drug shortage list would authorise it. The FDA has noted that this action does not itself govern 503A pharmacies, which operate under separate conditions. Separately, the HHS compounding enforcement policy posted on October 28, 2026 addresses a short list of other peptides and does not cover liraglutide, semaglutide or tirzepatide; those substances are governed by the 503B process described above rather than by that policy.

European Union. Victoza has held an EU-wide marketing authorisation since June 30, 2009 and Saxenda since March 23, 2015. Generic liraglutide pens have been authorised through the decentralised procedure since June 2024. The EMA has confirmed that the originator Victoza brand will be discontinued across the EU and EEA by the end of 2026 for commercial reasons, and has flagged the possibility of short-term intermittent supply disruption in some countries during the transition.

United Kingdom. Liraglutide holds a UK marketing authorisation for both indications, and a generic referencing Victoza was approved in March 2024. Access for weight management is shaped by NICE technology appraisal TA664, published on December 9, 2020, which positions liraglutide for managing overweight and obesity within a specialist (tier 3) weight management service alongside a reduced-calorie diet and increased physical activity, generally after other weight management interventions have been unsuccessful.

Australia. Saxenda was entered on the Australian Register of Therapeutic Goods on December 24, 2015 (ARTG 225804) and liraglutide is a Schedule 4 prescription-only substance. The TGA has also issued safety alerts regarding counterfeit products claiming to contain GLP-1 medicines, a reminder that supply outside the regulated pharmacy channel carries identity and sterility risks that no amount of product literature can offset. Legal status and reimbursement vary by jurisdiction and change over time; verify current status locally.

A reference guide is only as honest as its account of the gaps. Several questions about liraglutide remain open, and some are routinely treated as settled when they are not.

The cardiovascular benefit has not been demonstrated in people without diabetes. LEADER enrolled 9,340 people with type 2 diabetes and high cardiovascular risk. There is no comparable cardiovascular outcome trial of liraglutide in people with obesity and normal glucose metabolism. The LEADER hazard ratio of 0.87 belongs to the population that was studied and cannot be transferred to a different one.

The renal findings are narrower than the headline suggests. The LEADER renal composite was reduced, but the effect was driven primarily by new-onset persistent macroalbuminuria, a surrogate marker. Events in the harder components, persistent doubling of serum creatinine and end-stage kidney disease, were few. That is a hypothesis-generating secondary analysis, not proof that liraglutide prevents kidney failure.

Long-term weight maintenance beyond the trial windows is poorly characterised. The pivotal weight-management evidence runs to 56 weeks, and STEP 8 to 68 weeks. What happens to body weight over five or ten years of continuous use, and how much is regained after discontinuation, has not been established with the same rigour. Observational and extension data exist but do not carry the weight of a randomised trial.

There is no head-to-head trial against tirzepatide. Any numerical comparison between liraglutide and tirzepatide is cross-trial inference. The STEP 8 comparison against semaglutide is direct and robust; the tirzepatide comparison is not.

• No randomised evidence that liraglutide reduces cardiovascular events in people without diabetes.
• No established human relevance for the rodent thyroid C-cell tumour signal, in either direction.
• No adequately powered randomised data on multi-year weight maintenance or on post-discontinuation trajectories.
• No direct comparison against tirzepatide or against the dual and triple agonists now in development.
• No evidence base supporting unapproved liraglutide products obtained outside the regulated supply chain, where identity, purity and sterility are unverified.

This article is for educational purposes only and does not constitute medical advice. Liraglutide is a prescription medicine with a boxed warning and a substantial adverse effect profile, and decisions about its use belong with a qualified healthcare professional who can assess an individual's full clinical picture. Regulatory status, product availability and reimbursement differ by country and are changing rapidly.